Moreover, while a recent meta-analysis performed on a total of 10 studies showed that DPP-4is therapy is not able to determine a significant improvement in COVID-19 outcomes [47], another meta-analysis which included the aforementioned study by Solerte et al. [23], in addition to 2 studies considering the intrahospital use of DPP-4is [46,48], highlighted a significant reduction in terms of mortality among T2DM patients treated with such drugs; the association was weaker in patients who were also taking metformin and/or ACE inhibitors [49]. Here, ACE is linked to COVID-19.